Immunotherapy in non–small cell lung cancer: facts and hopes

DB Doroshow, MF Sanmamed, K Hastings, K Politi… - Clinical Cancer …, 2019 - AACR
K. Politi reports receiving commercial research grants from AstraZeneca, Roche, Symphogen,
and Kolltan, is coinventor on a patent licensed to Molecular MD for EGFR T790M mutation …

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

GJ Riely, KA Politi, VA Miller, W Pao - Clinical Cancer Research, 2006 - AACR
… but exhibit a higher K m for ATP and a lower K i for erlotinib relative to the wild-type receptor
(26). Separate in vitro kinase activity assays show that the catalytic efficiency (k cat /K M ) of …

Lung cancer in the era of precision medicine

K Politi, RS Herbst - Clinical cancer research, 2015 - AACR
K. Politi reports receiving a commercial research grant from AstraZeneca and Kolltan; is
listed as an inventor on a patent application for EGFR T790M mutation testing, which is licensed …

[HTML][HTML] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

W Pao, VA Miller, KA Politi, GJ Riely, R Somwar… - PLoS …, 2005 - journals.plos.org
Background Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors
gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations …

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

…, M Zakowski, J Doherty, K Politi… - Proceedings of the …, 2004 - National Acad Sciences
Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor
receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), …

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M …

…, GJ Riely, MG Kris, VA Miller, M Ladanyi, K Politi… - Cancer discovery, 2012 - AACR
… Rights to a patent application for EGFR T790M testing were licensed on behalf of VA
Miller, K. Politi, and W. Pao by Memorial Sloan-Kettering Cancer Center to MolecularMD. No …

[PDF][PDF] Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection

…, RC Orchard, B Lee, BD Lindenbach, K Politi… - Cell, 2021 - cell.com
Identification of host genes essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection may reveal novel therapeutic targets and inform our understanding of …

Cycling cancer persister cells arise from lineages with distinct programs

…, C Clish, AN Hata, E Zaganjor, G Lahav, K Politi… - Nature, 2021 - nature.com
… j, k, Time course of ROS levels in PC9 cells treated with osimertinib (j; P 0,3 … of metabolomics
data was generated using the umap R package with local connectivity of 2 and k = 3. …

Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer

…, DL Rimm, SM Kaech, K Schalper, RS Herbst, K Politi - Cancer discovery, 2017 - AACR
K. Politi reports receiving commercial research grants from AstraZeneca and Roche and
is a consultant/advisory board member for AstraZeneca, Novartis, and Merck. No potential …

[HTML][HTML] Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

…, IK Mellinghoff, MF Zakowski, KA Politi… - The Journal of …, 2009 - Am Soc Clin Investig
EGFR is a major anticancer drug target in human epithelial tumors. One effective class of
agents is the tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. These drugs …